Objective. Adipose tissues secrete adipokines, peptides with potent effects modulating fibrosis, inflammation, and vascular homeostasis. Dysregulated adipose tissue biology and adipokine balance have recently been implicated in systemic sclerosis (SSc). This study was undertaken to determine whether altered circulating adipokine levels correlate with SSc disease subsets or clinical manifestations.
B-type natriuretic peptide was. Moreover, in SSc patients, adipsin gene single-nucleotide polymorphisms were associated with PAH. Transcriptome data set analysis demonstrated elevated adipsin expression in patients with SSc-related PAH.
Conclusion. We identify adipsin as a novel adipose tissue-derived marker of SSc-related PAH. Circulating adipsin levels might serve as predictive biomarkers in SSc. Mechanistically, adipsin might represent a pathogenic link between adipocyte dysfunction and complement pathway activation and play an important role in the pathogenesis of SSc-related PAH.
Systemic sclerosis (SSc) is a devastating multisystem disorder that causes significant organ dysfunction, has no approved therapy, and has the highest mortality rate of any connective tissue disease. A hallmark of SSc is its marked heterogeneity, with substantial patient-topatient variations in clinical manifestations, autoantibody patterns, and disease outcomes. The pathogenesis of SSc is driven by autoimmunity, vascular damage, and tissue fibrosis. Skin fibrosis and Raynaud's phenomenon are the most common disease manifestations, while interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are leading causes of death (1) . The prognosis of SSc-related PAH is worse than that of idiopathic and other forms of PAH (2) .
Recent studies highlight an emerging role for adipose tissue and fat cells (adipocytes) in modulating fibrosis (3) . Patients with SSc have markedly attenuated intradermal white adipose tissue, and attrition of this adipose depot correlates inversely with increased skin fibrosis (4) . Adipokines, including leptin, adiponectin, resistin, visfatin, and adipsin, are peptides secreted from adipose tissue that have systemic paracrine and autocrine effects and play key roles in health and disease (5) . These adipokines modulate immune cell activation, vascular function, and fibrogenesis, processes that are central to SSc pathogenesis (6) .
Previous studies have revealed alterations in circulating adipokine levels in SSc patients (7) . However, to date only leptin and adiponectin have been thoroughly investigated, and the results have been variable. Moreover, the association of altered adipokine levels with SSc organ involvement has not been comprehensively assessed. In the present study, we tested the hypothesis that adipokines are dysregulated in SSc, that they are associated with clinical features, and that their levels may have prognostic value as biomarkers.
Our initial studies led us to focus on adipsin (also known as complement factor D), which was elevated in a subset of patients with limited cutaneous SSc (lcSSc), especially those with prevalent PAH. To assess a potential pathogenic role of adipsin in SSc, we queried adipsin genetic and gene expression data from SSc patients with and those without PAH. Our results identify adipsin as a potential biomarker for SSc-related PAH, and provide evidence suggesting that by linking adipose tissue dysfunction and complement pathway activation, it may play a role in the pathogenesis of SSc and SSc-related PAH.
PATIENTS AND METHODS
Patients. The study sample consisted of 198 patients with SSc evaluated at a single center. Patients were classified as having lcSSc (n 5 116) or diffuse cutaneous SSc (dcSSc; n 5 82) based on criteria proposed by LeRoy et al (8) . All patients fulfilled the American College of Rheumatology/ European League Against Rheumatism 2013 classification criteria (9) . Thirty-three healthy controls were also included. Patients underwent baseline clinical evaluation, pulmonary function testing, and echocardiograms, which were completed within 12 months of serum collection. Pulmonary hypertension (PH) was assessed both by echocardiography (echocardiographyproven PH was defined as systolic pulmonary artery pressure [ Determination of serum adipokine levels. Serum was collected during a standard-of-care blood draw. Levels of leptin, resistin, visfatin, adipsin, and adiponectin were determined using multiplex assay kits (Bio-Rad) according to the manufacturer's protocol. Samples were run in duplicate, and the coefficient of variation for adipsin was 6.7%. Measurement was performed on a Luminex 100 platform. Evaluation of correlation of serum adipokine levels with clinical parameters. We first compared clinical characteristics and levels of each adipokine in lcSSc versus dcSSc subgroups using chi-square and Fisher's exact tests (for categorical variables) and the Mann-Whitney U test (for continuous variables). In addition, we further subdivided lcSSc patients into those with high and those with low adipsin levels, with the cutoff value for high adipsin level defined as 2 SD above the mean in the control group. Next, we performed a multivariable logistic regression analysis to determine the independent association between adipsin and PAH. For additional description of the statistical methods used, see Supplementary Methods, available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40193/abstract.
Assessment of adipsin genetic polymorphisms and gene expression. Adipsin gene single-nucleotide polymorphisms (SNPs) were assessed using publicly available data from a genome-wide association study (GWAS) that included SSc patients with and SSc patients without PH determined by echocardiography (systolic PAP .40 mm Hg) (clinical data obtained with authorized access from dbGaP, accession no. phs000357.v1.p1). SNPs associated with SSc-related PAH were then assessed for the presence of expression quantitative trait loci (eQTLs) using expression data from the GTEx portal (www. gtexportal.org). Additionally, adipsin expression was assessed using publicly available data from both peripheral blood mononuclear cells (PBMCs) and lung tissue from SSc patients with and SSc patients without PAH (GEO accession nos. GSE19617and GSE22356). Further descriptions of the data sets and methods of analysis used are presented in the Supplementary Methods.
RESULTS
Adipokine levels in SSc. Compared to patients with dcSSc, patients with lcSSc had significantly higher levels of adiponectin (mean 6 SD 9.16 6 8.09 mg/ml versus 3.41 6 3.21 mg/ml; P , 0.0001), adipsin (mean 6 SD 1.51 6 1.25 mg/ml versus 0.71 6 0.22 mg/ml; P , 0.0001), leptin (mean 6 SD 20.38 6 33.19 ng/ml versus 8.35 6 10.09 ng/ml; P 5 0.002), and resistin (mean 6 SD 19.60 6 6.40 ng/ml versus 16.97 6 4.52 ng/ml; P 5 0.002) ( Table 1 ). Similar differences in adipokine levels were noted between lcSSc patients and controls. After correction for multiple hypothesis testing and adjustment for age, sex, race, body mass index (BMI), and disease duration (defined as the interval between the first nonRaynaud's phenomenon SSc symptom and serum collection), only levels of adiponectin (P 5 0.003) and adipsin (P 5 0.001) remained significantly different between the lcSSc and dcSSc subsets (Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40193/abstract). Further analysis focused on adipsin, also known as complement factor D, which has been implicated in the alternative complement pathway, but has not previously been linked to SSc.
Stratification of adipsin levels. Adipsin was substantially elevated in a subset of SSc patients, almost exclusively those with lcSSc ( Figure 1A) . Using a cutoff of 1.49 mg/ml (Figure 1B) (Figures 1E and F) . After adjustment for age, sex, BMI, disease duration, and disease subtype, the association between adipsin levels and echocardiographyproven PH remained significant (OR 7.7 [95% CI 2.1-21.0]; P , 0.001), but the association between adipsin level and PAH did not (OR 2.7 [95% CI 0.8-8.9]; P 5 0.10). Elevated adipsin levels were also associated with a reduction in diffusing capacity for carbon monoxide (DLCO), an increased ratio of FVC to DLCO, and lower values of tricuspid annular plane systolic excursion (TAPSE) and Doppler E 0 lateral velocity, which are indicative of right ventricular dysfunction and diastolic dysfunction, respectively ( Figures 1G-J 
4) (Figures 1I and J).
Stronger association between adipsin levels and SSc-related PAH than between B-type natriuretic peptide (BNP) levels and SSc-related PAH. BNP is widely used as a biomarker for SSc-related PAH (10) . Serum levels of BNP were elevated (.100 pg/ml) in 21% of SSc patients, while levels of adipsin were elevated in 16%. Elevated BNP was not significantly associated with PH defined by echocardiography (P 5 0.91) or PAH defined by invasive hemodynamic assessment (P 5 0.23), in contrast to elevated adipsin levels, which were significantly associated with both echocardiography-proven PH (P , 0.0001) and PAH defined by invasive hemodynamic assessment (P 5 0.001). High adipsin levels were more Figure 1 . Association of serum adipsin levels with limited cutaneous systemic sclerosis (lcSSc) and pulmonary arterial hypertension (PAH). A, Serum levels of adipsin in controls and SSc patients. There was no significant difference between the 2 groups. B, Higher adipsin levels in patients with lcSSc than in controls or patients with diffuse SSc (dcSSc). The broken line represents the upper cutoff value for adipsin. C-J, Association of SSc groups stratified by limited or diffuse cutaneous status and adipsin level with anticentromere antibodies (Ab) (C), anti-Scl-70 antibodies (D), pulmonary artery (PA) systolic pressure measured by echocardiography (E), PAH proven by right-sided heart catheterization (RHC) (F), ratio of forced vital capacity (FVC) to diffusing capacity for carbon monoxide (DLCO) (G), DLCO (H), tricuspid annular plane systolic excursion (TAPSE) (I), and E 0 lateral velocity (J). In A, B, E, and G-J, symbols represent individual subjects; horizontal lines and error bars show the mean and 95% confidence interval. In C, D, and F, bars show the mean 6 SD. In C-J, n 5 82 patients (81 with low adipsin) in the dcSSc group, n 5 86 patients in the lcSSc adipsin low group, and n 5 30 patients in the lcSSc adipsin high group. P values were determined by Mann-Whitney test. * 5 P , 0.01.
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specific for PAH than BNP levels (specificity of 85% versus 57% for PAH defined by invasive hemodynamic assessment), and receiver operating curve analysis demonstrated that adipsin had a greater area under the curve (AUC) than BNP for both echocardiography-proven Adipsin gene variants are associated with SScrelated PAH and modulate gene expression. To investigate whether elevated adipsin levels may be genetically determined in SSc-related PAH, we evaluated the association of polymorphisms in the CFD (adipsin) gene with SSc-related PAH using GWAS data (dbGAP phs000357.v1.p1). We analyzed data from 7 SNPs in the CFD region and assessed SNP allele frequencies in patients classified as having normal systolic PAP (,40 mm Hg; n 5 167) or elevated systolic PAP (.40 mm Hg; n 5 91) as determined by echocardiography. This strategy revealed that 4 of 7 CFD region SNPs (rs1683591, rs2365702, rs106044, and rs2965292) were associated with elevated PAP (Figure 2A) . To determine the potential functional consequences of the genetic association between CFD and PAH, we queried the GTEx portal. This analysis showed a significant eQTL effect in whole blood, with individuals carrying the minor allele of the PAH-associated SNPs showing increased adipsin expression ( Figure 2B ).
Increased adipsin expression in lcSSc patients with SSc-related PAH. Next, to determine if the genetic association of CFD SNPs with SSc-related PAH leads to dysregulated adipsin expression in tissue, we analyzed A B C Figure 2 . Genetic and expression studies demonstrating dysregulated adipsin in systemic sclerosis (SSc)-associated pulmonary arterial hypertension (PAH). A, List of 7 single-nucleotide polymorphisms (SNPs) in the adipsin (complement factor D) region on chromosome 19 genotyped in an SSc genome-wide association study (dbGAP accession no. phs000357.v1.p1). Minor allele frequencies (MAFs) for patients with SSc without pulmonary hypertension (PH) (systolic pulmonary artery pressure [PAP] .40 on echocardiography) and patients with SSc with PH (systolic PAP ,40 on echocardiography) are shown. Note that 4 of 7 SNPs in the region are associated with SSc-related PAH. Data were derived from dbGaP accession no. phs000357.v1.p1. B, Whole blood expression quantitative trait loci (eQTLs) SNPs. C, Elevated adipsin expression in peripheral blood mononuclear cells (PBMCs) from patients with limited cutaneous SSc (lcSSc) and patients with lcSSc with PAH (data derived from GEO accession no. GSE19617). In B and C, data are shown as box plots. Each box represents the 25th to 75th percentiles. Lines inside the boxes represent the median. Lines outside the boxes represent the maximum and minimum range. data from publicly available PBMCs and lung tissue microarrays. Data from 2 independent SSc cohorts (GEO accession nos. GSE19617 and GSE22356) demonstrated that circulating PBMCs from SSc patients with PAH had higher adipsin expression compared to patients without PAH ( Figure 2C and Supplementary  Figure 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art. 40193/abstract). In lung tissue obtained at the time of lung transplant, patients who received a transplant for SSc-related PAH also demonstrated elevated adipsin expression when compared to those who received a transplant for SSc-related ILD (accession no. GSE48149; data not shown).
DISCUSSION
We found that levels of multiple adipokines were significantly dysregulated in SSc. Our detailed analysis focused on adipsin for a number of reasons. First, the largest difference in adipsin levels was seen between lcSSc and dcSSc patients. Second, adipsin, which is also known as complement factor D, has not previously been associated with SSc or vascular disease. Most intriguing, adipsin has a unique role in linking adipose tissue function and complement pathway activation. In this analysis, we uncovered a robust association between elevated circulating levels of adipsin and SSc-associated PAH.
Patients with elevated adipsin levels were more likely to have the limited cutaneous form of SSc and were at significantly increased risk of PAH and related cardiac dysfunction. The association with PAH was confirmed by both echocardiography and hemodynamic data and further bolstered by associations with DLCO, the FVC:DLCO ratio, and measures of right ventricular function. While levels of leptin, resistin, and adiponectin were also elevated in lcSSc patients, they were not significantly associated with clinical markers of fibrosis or vascular disease, suggesting that while multiple adipokines are dysregulated in SSc, adipsin may be unique in its relationship with vascular outcomes such as PAH.
To begin to explore a potential involvement of adipsin in SSc pathogenesis, we queried publicly available data sets. The results indicate that adipsin gene variants are associated with increased PAH susceptibility. Moreover, SNPs associated with SSc-related PAH were associated with increased adipsin expression, SSc patients (particularly those with lcSSc) had elevated adipsin expression compared to controls, and patients with SScrelated PAH showed increased adipsin expression compared to SSc patients without PAH. Taken together, these findings suggest that elevated adipsin production may play a pathogenic role in SSc-related PAH. While we are unaware of studies evaluating adipsin in PAH, an intriguing study showed that a protease implicated in the pathogenesis of monocrotaline-induced PAH in rats is related to adipsin (11) .
Our analyses have certain limitations. First, in view of its cross-sectional design, the study is limited in its ability to assess the prognostic significance of adipsin. Future studies are planned to examine the prognostic value of baseline adipsin levels for predicting future outcomes such as clinical worsening, development of PAH, and the implications of changes in adipsin over time. Because the results of this study are Luminex based, future studies might use confirmatory enzyme-linked immunosorbent assay or other sensitive assays. Additionally, while we studied a relatively large and well-characterized cohort of SSc patients, the association of serum adipsin with SSc-related PAH will need to be validated in independent SSc cohorts. Moreover, the relatively small number of controls included in the present study (n 5 33) limits the power to detect adipokine differences between SSc patients and controls. Although genetic and gene expression data support a possible mechanistic relationship between adipsin, SSc, and PAH, functional studies will be required to demonstrate the role of adipsin in disease pathogenesis.
In contrast to adipokines such as leptin and adiponectin, adipsin has not been well studied, and its role in autoimmune/inflammatory/fibrotic disease has not been evaluated. Adipsin is one of the major adipocyte products and was the first adipokine described (12) . Subsequently, it was recognized to function as the serine protease complement factor D, which catalyzes the rate-limiting step of the alternative complement pathway, promotes the formation of the membrane-attack complex, and generates complement-signaling molecules, including the anaphylatoxins C3a and C5a (13) . Serum levels of adipsin decline in obesity, pregnancy, and type 2 diabetes mellitus, while elevated levels are seen in preeclampsia, but adipsin levels have not previously been assessed in patients with SSc or other rheumatic diseases (12) .
The pathogenic role of the complement cascade remains incompletely characterized in SSc. However, previous studies have described dysregulated complement activity in a subset of patients, particularly those with vascular disease. SSc patients have increased complement activation (14) , and activated complement complex C5b-9 and CD46 are present on arterioles in SSc skin biopsy specimens (15) . Moreover, SSc patients with vascular damage have elevated circulating levels of complement C3f desarginine (DRC3f) which enhances endothelial cell proliferation (16) .
Importantly, adipsin and complement cascade activation represent potential drug targets. In particular, lampalizumab, a pharmacologic inhibitor of adipsin, is currently in phase III clinical trials for macular degeneration, while eculizumab, a terminal complement inhibitor, has been approved for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome (HUS). Remarkably, eculizumab has been reported to induce remission in scleroderma renal crisis (a thrombotic microangiopathy that resembles atypical HUS), and to ameliorate pulmonary hypertension in patients with paroxysmal nocturnal hemoglobinuria (17) . If adipsin-mediated activation of the alternative complement pathway is shown to be pathogenic in SSc, in addition to marking a set of patients with severe vascular manifestations, this work may also identify a novel personalized and much needed treatment approach for this set of patients.
We demonstrate that circulating adipsin levels are elevated in patients with lcSSc and identify a significant association between elevated adipsin levels and PAH in this population. Genetic variants of adipsin are associated with SSc-related PAH, and adipsin gene expression was elevated in patients with SSc-related PAH. Taken together, these findings suggest a previously unrecognized pathogenic role for adipsin in SSc and SSc-related PAH and highlight adipsin as a novel marker of vascular manifestations with important prognostic and potentially therapeutic value. Moreover, in light of the essential role of adipsin in modulating complement pathway activity, our results implicate the complement system in SSc-related PAH.
